January 12, 2012European Heart Journal284 citationsOpen Access
Transcatheter aortic valve implantation: 3-year outcomes of self-expanding CoreValve prosthesis
View Full Paper
Structured PICO
Does transcatheter aortic valve implantation with the CoreValve prosthesis provide sustained clinical and echocardiographic benefits at 3 years in high-risk patients with symptomatic aortic stenosis?
P
Population
181 high-risk patients with symptomatic aortic stenosis from the Italian CoreValve registry who underwent TAVI from June 2007 to August 2008
I
Intervention
Transcatheter aortic valve implantation (TAVI) with the third generation CoreValve prosthesis (18-Fr CoreValve ReValving System)
O
Outcome
3-year clinical and echocardiographic outcomes including all-cause mortality, cardiovascular death, and a composite of death, major stroke, myocardial infarction, and life-threatening bleedingcomposite
TAVI with the CoreValve prosthesis provides sustained clinical and hemodynamic benefits up to 3 years in high-risk patients with symptomatic aortic stenosis, with no structural valve deterioration observed.
Abstract
AIMS: The paucity of evidences about the long-term durability of currently available transcatheter prostheses is one of the main issues of transcatheter aortic valve implantation (TAVI). We sought to assess 3-year clinical and echocardiographic outcomes of patients undergoing TAVI with the third generation CoreValve prosthesis (Medtronic Incorporation, MN, USA). METHODS AND RESULTS: From the Italian CoreValve registry, 181 who underwent TAVI from June 2007 to August 2008 and eligible for 3-year follow-up were analysed. All outcomes were defined according to the Valve Academic Research Consortium. All-cause mortality at 1, 2, and 3 years was 23.6, 30.3, and 34.8%, respectively. Cardiovascular death at 1, 2, and 3 years was 11.2, 12.1, and 13.5%, respectively. The actuarial survival free from a composite of death, major stroke, myocardial infarction, and life-threatening bleeding was 69.6% at 1 year, 63.5% at 2 years, and 59.7% at 3 years. Patients with renal insufficiency had a higher mortality at 3-year follow-up (49.0 vs. 29.2%, P = 0.007); moreover, patients experiencing post-procedural major or life-threatening bleeding had a higher rate of mortality already seen at 30 days (21.6 vs. 2.8%; P < 0.001) and this result was sustained at 3-year follow-up (62.2 vs. 27.7%; P < 0.001). Mean pressure gradients decreased from 52.2 ± 18.1 mmHg (pre-TAVI) to 10.3 ± 3.1 mmHg (1-year post-TAVI) (P < 0.001); aortic valve area increased from 0.6 ± 0.2 cm(2) (pre-TAVI) to 1.8 ± 0.4 cm(2) (1-year post-TAVI); these results remained stable over the 3 years of follow-up. Paravalvular leak was observed in the majority of patients. There were no cases of progression to moderate or severe regurgitation. No cases of structural valve deterioration were observed. CONCLUSION: This multicentre study demonstrates that TAVI with the 18-Fr CoreValve ReValving System is associated with sustained clinical and functional cardiovascular benefits in high-risk patients with symptomatic aortic stenosis up to 3-year follow-up. Non-cardiac causes accounted for the majority of deaths at follow-up.